Literature DB >> 18492108

Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome.

Davide Rossi1, Michaela Cerri, Daniela Capello, Clara Deambrogi, Francesca Maria Rossi, Antonella Zucchetto, Lorenzo De Paoli, Stefania Cresta, Silvia Rasi, Valeria Spina, Silvia Franceschetti, Monia Lunghi, Chiara Vendramin, Riccardo Bomben, Antonio Ramponi, Guido Monga, Annarita Conconi, Corrado Magnani, Valter Gattei, Gianluca Gaidano.   

Abstract

Predictors of chronic lymphocytic leukaemia (CLL) transformation to Richter syndrome (RS) are not established and were investigated in 185 consecutive CLL cases. Actuarial incidence of RS (n = 17; all diffuse large B-cell lymphomas) at 10 years was 16.2% (95% confidence interval: 8.0-24.4%). At CLL diagnosis, prognosticators of RS by univariate analysis were IGHV homology >/=98% (P = 0.006), IGHV4-39 usage (P < 0.001), del13q14 absence (P = 0.004), expression of CD38 (P < 0.001) and ZAP70 (P = 0.004), size (P < 0.001) and number (P < 0.001) of lymph nodes, advanced Binet stage (P = 0.002), and lactate dehydrogenase (P < 0.001). Multivariate analysis, performed separately for biological and clinical variables, identified CD38 expression [Hazard ratio (HR) = 4.26; P = 0.018], IGHV4-39 usage (HR = 4.29; P = 0.018), and lymph node size >/=3 cm (HR = 9.07; P < 0.001) as independent RS prognosticators. A multivariate model simultaneously analysing biological and clinical variables identified lymph node size >/=3 cm (HR = 6.51; P = 0.001) and del13q14 absence (HR = 4.08; P = 0.031) as independent RS prognosticators. Risk factors of CLL transformation differed from risk factors of CLL progression. These results suggest that CD38 and del13q14 may identify biological subsets of CLL with different RS predisposition. Predominant nodal disease, CD38 expression, IGHV4-39 usage, and absence of del13q14 may help in predicting RS at CLL diagnosis. Close monitoring and a careful biopsy policy are needed in patients carrying transformation risk factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18492108     DOI: 10.1111/j.1365-2141.2008.07166.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  53 in total

1.  Haematological cancer: Richter's transformation in CLL-a distinct lymphoma.

Authors:  Preetesh Jain; Ken H Young
Journal:  Nat Rev Clin Oncol       Date:  2013-11-26       Impact factor: 66.675

2.  Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia.

Authors:  Patricia Dos Santos; Julieta Panero; Virginia Palau Nagore; Carmen Stanganelli; Raimundo F Bezares; Irma Slavutsky
Journal:  Tumour Biol       Date:  2015-05-26

3.  Chest Wall Swelling, A Rare Presentation of Richter's Transformation.

Authors:  Javid Rasool; Samoon Jeelani; Sajad Jeelani; Afaq Khan; Mohd Suhail Lone
Journal:  Indian J Hematol Blood Transfus       Date:  2010-10-01       Impact factor: 0.900

4.  IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Authors:  D Rizzo; J Chauzeix; F Trimoreau; J B Woillard; F Genevieve; A Bouvier; J Labrousse; C Poli; E Guerin; N Dmytruk; L Remenieras; J Feuillard; N Gachard
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

5.  How we treat Richter syndrome.

Authors:  Sameer A Parikh; Neil E Kay; Tait D Shanafelt
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

Review 6.  Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Authors:  Mohamed A Kharfan-Dabaja; Ambuj Kumar; Mehdi Hamadani; Stephan Stilgenbauer; Paolo Ghia; Claudio Anasetti; Peter Dreger; Emili Montserrat; Miguel-Angel Perales; Edwin P Alyea; Farrukh T Awan; Ernesto Ayala; Jacqueline C Barrientos; Jennifer R Brown; Januario E Castro; Richard R Furman; John Gribben; Brian T Hill; Mohamad Mohty; Carol Moreno; Susan O'Brien; Steven Z Pavletic; Javier Pinilla-Ibarz; Nishitha M Reddy; Mohamed Sorror; Christopher Bredeson; Paul Carpenter; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-19       Impact factor: 5.742

Review 7.  Molecular pathogenesis of chronic lymphocytic leukemia.

Authors:  Gianluca Gaidano; Robin Foà; Riccardo Dalla-Favera
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

8.  An integrated Bayesian analysis of LOH and copy number data.

Authors:  Paola M V Rancoita; Marcus Hutter; Francesco Bertoni; Ivo Kwee
Journal:  BMC Bioinformatics       Date:  2010-06-15       Impact factor: 3.169

9.  Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells.

Authors:  Till Seiler; Manuela Woelfle; Sophia Yancopoulos; Rosa Catera; Wentian Li; Katerina Hatzi; Carol Moreno; Marcela Torres; Santanu Paul; Hartmut Dohner; Stephan Stilgenbauer; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  Blood       Date:  2009-08-18       Impact factor: 22.113

Review 10.  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Authors:  Michele Dal-Bo; Francesco Bertoni; Francesco Forconi; Antonella Zucchetto; Riccardo Bomben; Roberto Marasca; Silvia Deaglio; Luca Laurenti; Dimitar G Efremov; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2009-08-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.